ArticleOncoTargets and therapy2019

Complete response to crizotinib in a metastatic adenocarcinoma of unknown primary harboring MET amplification and NTRK1 co-occurring mutation.

Jing-Hao Yao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.